Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elements.
p53 coordinates the expression of an intricate network of genes in response to stress signals. Sequence-specific DNA binding is essential for p53-mediated tumor suppression. We evaluated the impact of single-nucleotide polymorphisms (SNPs) in p53 response elements (p53RE) on DNA binding and gene expression in response to DNA damage. Using a bioinformatics approach based on incorporating p53 binding strength into a position weight matrix, we selected 32 SNPs in putative and validated p53REs. The microsphere assay for protein-DNA binding (MAPD) and allele-specific expression analysis was employed to assess the impact of SNPs on p53-DNA binding and gene expression, respectively. Comparing activated p53 binding in nuclear extracts from doxorubicin- or ionizing radiation (IR)-treated human cells, we observed little difference in binding profiles. Significant p53 binding was observed for most polymorphic REs and several displayed binding comparable to the p21 RE. SNP alleles predicted to lower p53 binding indeed reduced binding in 25 of the 32 sequences. Chromatin immunoprecipitation-sequencing in lymphoblastoid cells confirmed p53 binding to seven polymorphic p53 REs in response to doxorubicin. In addition, five polymorphisms were associated with altered gene expression following doxorubicin treatment. Our findings demonstrate an effective strategy to identify and evaluate SNPs that may alter p53-mediated stress responses.
Bandele
Omari J
OJ
Environmental Genomics Group, Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA.
Wang
Xuting
X
Campbell
Michelle R
MR
Pittman
Gary S
GS
Bell
Douglas A
DA
D000483:Alleles; D001665:Binding Sites; D002478:Cells, Cultured; D047369:Chromatin Immunoprecipitation; D019295:Computational Biology; D004249:DNA Damage; D004317:Doxorubicin / Q000494:pharmacology; D006801:Humans; D020641:Polymorphism, Single Nucleotide; D011485:Protein Binding; D020218:Response Elements; D017422:Sequence Analysis, DNA; D014158:Transcription, Genetic / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D004317:Doxorubicin
Bioinformatics. 2009 Jul 15;25(14):1754-60
19451168
Cell. 1994 Dec 2;79(5):817-27
8001119
J Cancer Res Clin Oncol. 1998;124(2):117-26
9654195
Proc Natl Acad Sci U S A. 2005 May 3;102(18):6431-6
15843459
Cancer Res. 2008 Dec 1;68(23):9671-7
19047144
Biochem Biophys Res Commun. 2002 Mar 29;292(2):492-7
11906189
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1406-11
16432214
J Biol Chem. 1996 Jun 14;271(24):14412-20
8662930
Environ Health Perspect. 2003 Jun;111(8):1055-64
12826477
Oncogene. 2008 Jul 3;27(29):4013-23
18278067
PLoS Genet. 2008 Jun 27;4(6):e1000104
18714371
Mol Cell. 2003 Oct;12(4):1015-27
14580351
Cell. 2006 Jan 13;124(1):207-19
16413492
Mol Cell Biol. 1992 Jun;12(6):2866-71
1588974
Nat Genet. 2003 Apr;33(4):439-40
12665861
Cancer Res. 2009 Nov 1;69(21):8463-71
19843844
Mol Biol Evol. 2002 Jul;19(7):1114-21
12082130
Hum Mol Genet. 2007 May 15;16(10):1188-200
17409198
J Hum Genet. 2003;48(9):447-450
12955585
Mutat Res. 2004 May 9;560(1):1-10
15099818
Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):1998-2002
8134338
PLoS Genet. 2007 Jul;3(7):e127
17677004
Cancer Res. 2005 Apr 15;65(8):3428-36
15833878
EMBO J. 2000 Sep 15;19(18):4967-75
10990460
FEBS Lett. 1999 Nov 26;462(1-2):85-8
10580097
Mol Cell Biol. 2002 Dec;22(24):8612-25
12446780
Nat Rev Mol Cell Biol. 2008 May;9(5):402-12
18431400
Genes Immun. 2001 Apr;2(2):105-9
11393654
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11936-41
11035798
Mol Cell Biol. 2006 Oct;26(19):7030-45
16980608
Cancer Immunol Immunother. 2006 Apr;55(4):355-62
16187084
Nat Genet. 1999 Jun;22(2):145-50
10369255
Mol Endocrinol. 2003 Mar;17(3):356-65
12554766
Cancer Res. 2003 Apr 15;63(8):1756-8
12702557
Mol Cell Biol. 2006 Sep;26(18):6859-69
16943427
Hum Mol Genet. 1994 Sep;3(9):1537-42
7833908
Leuk Res. 2007 Jul;31(7):995-1001
17257675
Cell. 2004 Feb 20;116(4):499-509
14980218
Proteomics. 2006 Jan;6(2):498-504
16317774
Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):84-90
16002116
Nucleic Acids Res. 2003 Jul 15;31(14):e73
12853650
Cancer Res. 2002 Dec 15;62(24):7316-27
12499275
Nucleic Acids Res. 2007;35(9):2986-3001
17439973
Oncogene. 2004 May 20;23(23):4050-9
15064739
PLoS Genet. 2009 May;5(5):e1000462
19424414
J Clin Endocrinol Metab. 2004 Jan;89(1):344-51
14715870
Oncogene. 2007 Apr 2;26(15):2191-201
17401428
Nat Genet. 1992 Apr;1(1):45-9
1301998
Nucleic Acids Res. 2008 Mar;36(5):1589-98
18234719
Nat Methods. 2008 Sep;5(9):829-34
19160518
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14373-8
19597154
Genes Dev. 2000 Apr 15;14(8):981-93
10783169
Mol Biol Rep. 1997 Mar;24(1-2):57-62
9228282
Genome Res. 2007 Nov;17(11):1586-95
17908822